Three in one: Safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 555-563

  Taylor, Addison A ^a   Ragbir, Shawn ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Calcium channel blockers; Hypertension; Patient tolerability; Renin angiotensin system antagonists; Safety; Triple drug combinations

Indexed keywords

ALISKIREN PLUS AMLODIPINE; ALISKIREN PLUS AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE PLUS DIHYDROPYRIDINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS PERINDOPRIL; AMLODIPINE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATENOLOL PLUS BENDROFLUMETHIAZIDE; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; PERINDOPRIL; PLACEBO; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNITED STATES;

EID: 84873242623     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S14764     Document Type: Review

References (58)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
3. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913.
4. Verdecchia P, Reboldi G, Angeli F, et al. Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects. Hypertension. 2004;43:01.
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
6. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761-2788.
7. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA. 1997;277(16):1293-1298.
8. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA. 1997;278(23):2069-2074.
9. Young JH, Klag MJ, Muntner P, Whyte JL, Pahor M, Coresh J. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J Am Soc Nephrol. 2002; 13(11):2776-2782.
10. Chobanian A, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
11. Julius S, Kjeldsen S, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
12. Staessen JA, Thijisq L, Fagard R, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22(4):847-857.
13. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306(23):2588-2593.
14. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046-1058.
15. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90-98.
16. Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010;12(11):869-878.
17. Weber M, Julius S, Kjeldsen S, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049-2051.
18. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
19. SHEP Coop Res Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265(24):3255-3264.
20. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
21. Cushman WC, Ford CE, Einhorn PT, et al. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering TReatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2008;10(10):751-760.
22. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-1762.
23. Sheps SG, Black HR, Cohen JD, et al. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med. 1997;157:2413-2446.
24. VA Cooperative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967;202(11):1028-1034.
25. Dollery CT. Pharmacological basis for combination therapy of hypertension. Annu Rev Pharmacol Toxicol. 1977;17:311-323.
26. The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984;144(5):1045-1057.
27. 1988 Joint National Committee. The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1988;148:1023-1038.
28. Kaplan N. Low dose combinations in the treatment of hypertension: theory and practice. J Hum Hypertens. 1999;13(10):707-710.
29. Stern N, Grosskopf I, Shapira I, et al. Risk factor clustering in hypertensive patients: impact of the reports of NCEP-II and second joint task force on coronary prevention on JNC-VI guidelines. J Intern Med. 2000;248(3):203-210.
30. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
31. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
32. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427-1434.
33. Oparil S, Melino M, Lee J, Fernandez V, Heyrman R. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010;32(7):1252-1269.
34. Chrysant SG, Izzo JL, Kereiakes DJ, et al. Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study. J Am Soc Hypertens. 2012;6(2)132-141.
35. Chrysant SG, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of olmesartan medoxomil (OM) + amlodipine (AML)hydrochlorothiazide(HCTZ) in patients with hypertension analyzed by age and gender: The Trinity Study: Pp 5.185 [Abstract]. J Hypertens. 2010;28[e-supplement A]:e103.
36. Kereiakes D, Chrysant SG, Melino M, Fernandez V, Lee J. Efficacy and safety of combination olmesartan medoxomil (OM) + amlodipine besylate(AML) + hydrochlorothiazide (HCTZ) based on severity of hypertension: The Trinity Study: PP.5.164 [Abstract]. J Hypertens. 2010;28[e-supplement A]:e97.
37. Littlejohn T, Melino M, Fernandez V, Lee J, Heyrman R. Efficacy and safety of combiantion olmesartan medoxomil (OM) + amlodipine besylate (AML)hydrochlorothiazide (HCTZ) based on race: The Trinity Study: Pp. 5.172 [Abstract]. J Hypertens. 2010;28[e-supplement A]:e99-e100.
38. Izzo JL Jr, Chrysant GS, Kereiakes DJ, et al. 24-Hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: The TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich). 2011;13(12):873-880.
39. Calhoun DA, Lacourciere Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32-39.
40. Lacourcière Y, Crikelair N, Glazer RD, Yen J, Calhoun DA. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25(10):615-622.
41. Novartis. Efficacy and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate-severe hypertension. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated April 15, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00765674?term=NCT00765674&rank=1. NLM identifier: NCT00765674. Accessed May 11, 2012.
42. Ferdinand KC, Weitzman R, Israel M, et al. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens. 2011;5(2):102-113.
43. Novartis. A long term safety study to test the combination of aliskiren/amlodipine/hydrochlorothiazide in patients with essential hypertension. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated August 22, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00667719?term=NCT00667719&rank=1. NLM identifier: NCT00667719. Accessed May 12, 2012.
44. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009;24(5):1663-1671.
45. Swales JD, Bing RF, Heagerty A, et al. Treatment of refractory hypertension. Lancet. 1982;1(8277):894-896.
46. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents-a preliminary report. Hypertension. 2007;49(2):272-275.
47. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
48. Lummis HL, Sketris IS, Gubitz GJ, Joffres MR, Flowerdew GJ. Medication persistence rates and factors associated with persistence in patients following stroke: a cohort study. BMC Neurol. 2008;8:25.
49. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag. 2008;4(3):673-681.
50. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460-467.
51. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care. 2000;10(Suppl 10):6-10.
52. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ. 2011;14(5)576-583.
53. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24(9):2597-2607.
54. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
55. Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898-909.
56. Taylor AA, Shoheiber O. Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. Congest Heart Fail. 2003;9(6):324-332.
57. Dickson M, Plauschinat CA. Racial differences in medication compliance and healthcare utilization among hypertensive Medicaid recipients: fixed-dose vs free-combination treatment. Ethn Dis. 2008;18(2):204-209.
58. Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens. Curr Med Res Opin. 2010;26(12):2877-2887.